Kornimate/medical-research-clean huggingface dataset:
effects of high intensity interval training (hiit) vs. inspiratory muscle training on the recovery after a maximal apnea.

Conditions: Exercise Training; Respiratory Muscle Training; High-Intensity Interval Training; Apnea

Summary: the aim of this randomized cross-over controlled study was to assess the effects of an 4-week exercise program on the recovery capacity after a voluntary maximal apnea. participants will be randomly allocated to receive either a high intensity interval training (hiit), or an inspiratory muscle training (imt) using an inspiratory resistance device.

it is a multi-center study. 3 different spanish freedivers centres are included in the study (madrid, zaragoza, and barcelona). for each participant, exercise program started with one or the other program. hence, both interventions were applied once with the participant randomly allocated to receive the same intervention. the trial included four study visits. each exercise training program will be applied sessions per week during 4 weeks. participants received baseline assessments at the beginning of nay intervention, and post-intervention assessments at the end of the fourth week. the wash-out period will be two weeks. after these two weeks participants switched intervention.

Eligibility criteria:
inclusion criteria: * absence of pain or illness * no changes in cognitive ability * over 18 years old. * member of the spanish federation of underwater activities. * positive medical examination that allows the diver to practice voluntary apnea. exclusion criteria: * people with systemic diseases, tumors, infections, pacemakers, history of epilepsy, hydrophobia, pregnancy women, pharmacological treatment. * to be participating in other physical activities during the experimental research
study of roxadustat in non-dialysis chronic kidney disease participants with anemia

Conditions: Chronic Kidney Disease; Anemia

Summary: the primary purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with non-dialysis chronic kidney disease.


Eligibility criteria:
inclusion criteria: 1. age 18 to 75 years 2. chronic kidney disease, not receiving dialysis 3. body weight 45 to 140 kg exclusion criteria: 1. any clinically significant infection or evidence of an underlying infection 2. positive for any of the following: human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or anti-hepatitis c virus antibody (anti-hcv ab) 3. history of chronic liver disease 4. new york heart association class iii or iv congestive heart failure 5. myocardial infarction or acute coronary syndrome within 12 weeks prior to randomization 6. history of malignancy 7. chronic inflammatory disease that could impact erythropoiesis (for example, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission 8. history of myelodysplastic syndrome, multiple myeloma, or pure red cell aplasia 9. history of hemosiderosis, hemochromatosis or polycystic kidney disease 10. active hemolysis or diagnosis of hemolytic syndrome 11. uncontrolled or symptomatic secondary hyperparathyroidism 12. seizure disorder or receiving anti-epilepsy medication 13. known bone marrow fibrosis 14. any prior or scheduled organ transplant 15. prior treatment with roxadustat or any hypoxia-inducible factor prolyl hydroxylase inhibitor 16. history of alcohol or drug abuse

Keywords: kidney chronic kidney disease ckd renal anemia oral anemia treatment hemoglobin levels erythropoietin blood count predialysis pre-dialysis hb non-dialysis
a study to assess the severity of psoriasis in brazilians participants with chronic plaque-type psoriasis

Conditions: Psoriasis; Plaque

Summary: the purpose of this study is to assess the severity of plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. the lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region) in brazilian participants with chronic plaque-type psoriasis.

this is a cross-sectional (studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time), observational (clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions), non-interventional, multicenter study (when more than one hospital or medical school team work on a medical research study). participants with plaque psoriasis will be followed up at specialized dermatology centers. participants will undergo assessment at a single time point and all assessments will be conducted on the same day. information will be collected about disease severity/ socioeconomic variables and demographics; clinical characteristics; treatment (current and past procedures and therapies to treat psoriasis); quality of life; and comorbidities identified after plaque psoriasis was diagnosed. the information will be obtained from the medical records, as requested, and during the medical interviews. the primary objective of this study is to assess the severity of plaque-type psoriasis.

Eligibility criteria:
inclusion criteria: * participant diagnosed with chronic plaque psoriasis * participant is at least 18 years old * participant is able to understand and sign the informed consent form exclusion criteria: * in the opinion of the investigator, the participant is unable or unavailable to complete all study procedures * participant suffers from a psychiatric condition or any other clinical condition that might interfere with the ability to understand the study requirements * participant refuses consent or is unwilling to supply the required information within the required period * participant is taking part in an interventionist clinical trial with an investigational agent (i.e. non-commercialized agent) or in an interventionist clinical trial sponsored by johnson \& johnson * participant is an employee of the investigator or study site and is directly involved in the conduction of this study or other studies conducted by the same investigator at the same site, or is a family member of the employee or investigator

Keywords: psoriasis plaque chronic
study of wal0921 in patients with glomerular kidney diseases

Conditions: Diabetic Nephropathies; Primary Focal Segmental Glomerulosclerosis; Minimal Change Disease; Primary Immunoglobulin A Nephropathy; Primary Membranous Nephropathy

Summary: this is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of wal0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[fsgs\], treatment-resistant minimal change disease \[tr mcd\], primary immunoglobulin a nephropathy \[igan\], and primary membranous nephropathy \[pmn\]). subjects in this study will be randomized to receive the investigational drug wal0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. all subjects will be followed for 24 weeks after their last infusion.


Eligibility criteria:
inclusion criteria: * adults, age 18-75 years * diagnosis of one of the following glomerular kidney diseases: diabetic nephropathy; primary focal segmental glomerulosclerosis; treatment resistant-minimal change disease; primary iga nephropathy; primary membranous nephropathy * egfr greater than or equal to 30 ml/min/1.73 m2 exclusion criteria: * currently pregnant or planning to become pregnant * history of organ transplantation * history of alcohol or substance use disorder * acute dialysis or acute kidney injury within 6 months of screening * any prior or current medical condition that, in the judgment of the investigator, would prevent the subject from safely participating in and/or completing all study requirements

Keywords: dn fsgs tr-mcd igan pmn
adverse events related to low dose atropine

Conditions: Myopia, Progressive

Summary: progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. many eye care providers are now prescribing off-label atropine eye drops for their myopic patients, with the prescribed concentrations varying amongst providers. the purpose of this study is to determine if low-dose atropine eyedrops used daily, cause adverse effects to the eyes. patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops obtained from compounding pharmacies will be assessed for associated adverse effects.

eligibility: myopic patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops, prescribed by the investigator(s). patients that meet the eligibility criteria will be given the parental consent form and child assent form (if applicable) during their regularly scheduled office visit. after consent forms are signed and at each follow-up visit, the investigator or study coordinator will begin by querying for adverse events by asking each patient general, non-directed questions, such as "how have you been feeling since the last visit?" directed questioning and examination will then be done as appropriate. all reported adverse events will be documented on the appropriate crf. the patients will then continue with their regular eye exam. patients enrolled in the study will be assessed for adverse events at each regularly scheduled office visit for the duration of the study (up to 5 years), unless they choose to withdraw from the study. the study will assess 148 patients using either 0.01%, 0.03%, or 0.05% atropine eye drops (prescribed by the investigator), over a five-year period.

Eligibility criteria:
inclusion criteria: * patients diagnosed with myopia * patients must be currently using 0.01%, 0.03%, or 0.05% atropine eye drops daily * low-dose atropine eye drops must be prescribed by the principal investigator and obtained from a compounding pharmacy exclusion criteria: * patients without myopia * patients with myopia, but not using low-dose atropine eye drops

Keywords: adverse events nearsightedness atropine
shared decision-making: effects on cardiac risk factor modification behavior

Conditions: Coronary Artery Disease; Decision Making

Summary: decision aids (da) to inform patients about health care options and help them to participate in their care choices are widely advocated. the main argument for offering patients a choice is that patients' preferences vary, and health professionals cannot always know what is "best" for an individual, specially when different outcomes have different benefits and risk profiles. the standard modes of treatment for patients with coronary artery disease (cad) are coronary artery bypass graft (cabg) surgery, medication, and angioplasty. all three treatments for cad work better when combined with cardiac risk factor modification behavior (crfmb). crfmb is important for the general public, but it is even more important for people with cad because people with cad have more at stake. in this rct study we will evaluate the effectiveness of a cad-da with and witout an additional decision counseling program (dcp) on health outcomes and quality of life to improve enhancement of adherence to cardiac risk modification behavior. the cad-da is developed by the ottawa health research institute and division of clinical epidemiology at montreal general hospital, for cad patients facing the decision of making lifestyle changes to lower their cardiac risk factors. it provides patients with information about what they can you do to prevent the disease from progressing. the dcp is designed to systematically guide patients through the process of deciding what cardiac risk modification behaviors are important for them to carry out. a rct where 360 cad patients \> 18 of age scheduled for an angiogram at rikshospitalet university hospital in norway (rh) will be randomly assigned to: (1) cad-da group where subjects will receive, for take home, the cad-da prior to their scheduled angiogram; (2) dcp group where subjects in addition to the cad-da will receive an individual decisional counseling program (dcp) from a trained nurse counselor in their homes prior to their angiogram; and (3) the control group who will receive "usual care". data will be collected at four points: at the initial visit (t1), 2 months (t2), 4 months (t3) and 6 (t4) months after angiogram

as above

Eligibility criteria:
inclusion criteria: * age 18 and older * scheduled for an angiogram * able to read, write, and speak norwegian * live within approximately 100 km of oslo * have a telephone exclusion criteria: - cognitive impairment

Keywords: risk factors risk reduction behavior counseling
a study of albuferon with ribavirin in interferon treatment experienced subjects with chronic hepatitis c

Conditions: Hepatitis C

Summary: this is a phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of albuferon in subjects with hepatitis c (hep c) who failed to respond to previous interferon alfa therapy.


Eligibility criteria:
major inclusion criteria: * have a clinical diagnosis of chronic hep c established on the basis of detectable viral load, as measured by a serum hcv rna test during the screening period. * have previously failed to respond to treatment with any interferon alfa (ifna) product * have compensated liver disease with the following minimum criteria: white blood cell count \> 3,000/mm3, absolute neutrophil count (anc) \> 2,000/mm3, platelets \> 125,000/mm3, and hemoglobin (hb) \> 13 g/dl for males or \> 12 g/dl for females. major exclusion criteria: * evidence of decompensated cirrhosis or portal hypertension. * pregnant or lactating female. * history of any other medical disease or condition that would make the subject (in the opinion of the investigator) unsuitable for the study. * a current drug or alcohol addiction
telehealth approach to enhancing glycemic control

Conditions: Diabetes Mellitus

Summary: this study evaluates whether the use of a continuous glucose monitoring (cgm) device combined with a remote patient monitoring (rpm) program can improve blood sugar control and reduce hospital visits among patients with poorly controlled diabetes who have recently been discharged from the hospital. the study, led by white plains hospital (wph) cares, will follow 208 patients for 90 days after their discharge. half of the participants will receive standard care, while the other half will receive a dexcom g7 cgm device along with support from trained nurses who will monitor their glucose readings daily. the goal is to determine whether this approach helps lower hemoglobin a1c (hba1c) levels, reduces hospital readmissions, and improves overall health outcomes.


Eligibility criteria:
inclusion criteria: * discharged home from the wph inpatient setting a1c \>= 8.0 within 90 days of discharge \>= 18 years of age lives within westchester county exclusion criteria: * \<18 years of age patient with documented cognitive impairment or decisional incapacity pregnant or plans to become pregnant in 6 months discharge disposition of short-term or long-term care facility, assisted living facility, group home, against medical advice/eloped, or home hospice patient or caregiver unable to check glucose at home using a home glucometer lives outside westchester county

Keywords: diabetes continuous glucose monitoring remote patient monitoring
pet / mr with psma for diagnosis and staging of hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: assess the rate and degree of psma uptake in patients with hepatocellular carcinoma submitted to pet/mri scans. the objective is to evaluate its value on diagnosis and staging of hcc.

pet/mr - psma have emerged as a new method and there are few studies about its role in the evaluation of hepatocellular carcinoma (hcc). the hypothesis in this study is that pet/mri with psma might have an additional value in the assessment of hepatocellular carcinoma, contributing to the diagnosis of distant metastasis and to confirm the diagnosis in undetermined nodules by the standard exams (computed tomography and magnetic resonance imaging). patients with hepatocellular carcinoma diagnosed by computed tomography or magnetic resonance imaging and referred to a liver transplant or surgery by clinical decision wil be submitted to a whole-body psma-pet/mri and will be included in this prospective unicentric study to be conducted at instituto do câncer do estado de são paulo (icesp) and hospital das clínicas da faculdade de medicina da universidade de são paulo (hc-fmusp). all cases will be evaluated to determine the presence and degree of psma uptake on lesions considered as definitely hccs by ct or mri. the sensitivity of psma - pet/mr for the diagnosis of hcc will be calculated. the added value of psma - pet mr on systemic staging will be calculated by the number of lesions considered suspicious for malignancy that were not detected by conventional scans.

Eligibility criteria:
inclusion criteria: * patients with an imaging diagnosis of hcc by a previous ct or mri, reviewed by an abdominal radiologist * patients candidates to liver transplant or surgical resection exclusion criteria: * patients with treated liver lesion without viable tumor * age under 18 * pregnancy * patients with renal insufficiency; * elevated bilirubin levels (\>3 mg/dl) * known allergy to contrast media (gadoxetic acid) or radiotracer (psma); * blood glucose level higher than 150 mg/dl. * mr contraindications (claustrophobia, cardiac pacemakers, neurostimulators, cochlear implants, and insulin pumps).

Keywords: positron emission tomography/magnetic resonance) (pet/mr) magnetic resonance imaging hepatocellular carcinoma
clinicopathological features of nsclc patients associated with the chromosome 2p (eml4-alk)

Conditions: Non Small-cell Lung Cancer

Summary: because alk-positive lung cancer constitutes less than 5% of all lung cancers, it is critically important to select those patients who are more likely to have the alk mutation. clinical characteristics of patients with mutations in the target gene should also be known, so that the incidence of a given target mutation is established in a specific population. there is not incidence known in mexican population, but it is believed it is greater.

lung adenocarcinoma studies. the only inclusion criterion was the availability of tissue for biomarker studies. to identify alk rearrangements, fluorescence in situ hybridization (fish) studies were performed on 3 to 4 mm thick paraffin sections from nsclcs. the commercially labeled vysis lsi alk dual color (split-apart), break-apart rearrangement probe (abbott molecular, abbott park, il) was used to detect any rearrangement involving the alk gene. the probe hybridizes to band 2p23, on either side of the alk gene breakpoint. criteria for probe signal interpretation in at least 200 interphase nuclei were as follow: 1) separated green and orange signals or single red signals identified cells with rearranged alk; 2) overlapping of red and green signals (yellowish) indicated cells in which alk was not rearranged. fish-positive samples for alk rearrangement were defined as having cells with a clearly separated pair of probe signals, or with \>15% of cells having loss of the 5´(centromeric) probe. the higher threshold for loss is necessary because parts of probes can be lost during sectioning. the aim of our study is to evaluate the utility of ihc with 5a4 and rt-qpcr in the detection of alk rearrangements in nsclc compared with the current method of choice, fish. further, we report on the demographics, and clinicopathologic features of alk-rearranged nsclc in a latin-american population. clinical details of these patients were included in a database. further results will be analyzed with the program spss17

Eligibility criteria:
inclusion criteria: * the only inclusion criterion was the availability of tissue for biomarker studies. exclusion criteria: * disease progression

Keywords: non-small cell lung cancer. diagnosis, adenocarcinoma, alk, fish, ihc rt-qpcr
pediatric bipolar disorder study at ucla

Conditions: Bipolar Disorder

Summary: the ucla semel institute for neuroscience in los angeles, ca, is conducting a study looking at similarities and differences in how the brain works between bipolar disorder and attention deficit hyperactivity disorder (adhd).

children between the ages of 7 and 17 years old, with a diagnosis of bipolar i, bipolar ii, or bipolar nos, are currently being recruited for this study looking at similarities and differences in how the brain works between bipolar disorder and attention deficit hyperactivity disorder (adhd). the study involves a comprehensive evaluation at intake, cognitive assessment, eeg, and functional mri, done over the course of 2 or 3 visits. this study does not provide treatment. however, with participants' consent, the assessment information can be shared with the child's clinician or psychiatrist and a letter with the results from cognitive testing can be prepared, which can be useful in school planning. referrals for treatment can also be provided.

Eligibility criteria:
inclusion criteria: * subject suffers clinically impairing symptoms of mood lability. * child has resided with primary caretaker for at least 6 months. * caretaker speaks sufficient english to complete all study evaluations and measures. exclusion criteria: * lifetime history of mental retardation, autism, or primary diagnosis of psychosis. * subject is pregnant or nursing.

Keywords: bipolar disorder child bipolar disorder adolescent bipolar disorder pediatric bipolar disorder fmri mri eeg neurocognitive tasks